Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (6)
  • Autophagy
    (15)
  • DNA/RNA Synthesis
    (9)
  • HCV Protease
    (16)
  • HIV Protease
    (15)
  • Influenza Virus
    (6)
  • Parasite
    (8)
  • SARS-CoV
    (173)
  • Virus Protease
    (7)
  • Others
    (200)
Filter
Search Result
Results for "SARS-CoV" in TargetMol Product Catalog
  • Recombinant Protein
    459
    TargetMol | Activity
  • Inhibitor Products
    405
    TargetMol | inventory
  • Natural Products
    32
    TargetMol | natural
  • Antibodies Products
    26
    TargetMol | composition
  • Peptides Products
    8
    TargetMol | Activity
  • Dye Reagents
    4
    TargetMol | inventory
  • Isotope products
    4
    TargetMol | natural
  • Compound Libraries
    2
    TargetMol | composition
SARS-CoV-2 Mpro-IN-2
T630982768834-39-3In house
SARS-CoV-2 Mpro-IN-2 is a selective SARS-CoV-2M pro inhibitor with an IC50 value of 0.40 μM.SARS-CoV-2 Mpro-IN-2 has good antiviral activity and can be used to study COVID-19.
  • $397
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2 3CLpro-IN-16
T79659352659-40-6In house
SARS-CoV-2 3CLpro-IN-16 is a covalent SARS-CoV-2 3CLpro inhibitor that inhibits 3CLpro activity and achieves its inhibitory effect by forming a covalent bond with Cys145.
  • $195 TargetMol
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-64
T81207
SARS-CoV-2-IN-64 (compound 9), derived from chenodeoxycholic acid, serves as a potent inhibitor of the SARS-CoV-2 spike glycoprotein [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-62
T812092350285-18-4
SARS-CoV-2-IN-62 (Compound R3b) effectively inhibits SARS-CoV-2 replication in Vero E6 and Calu-3 cells, demonstrating low cytotoxicity and EC50 values of 2.97 μM and 3.82 μM, respectively [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-63
T812082350285-21-9
SARS-CoV-2-IN-63 (Compound R3e) serves as an inhibitor of SARS-CoV-2 replication, demonstrating low cytotoxicity. It effectively suppresses viral replication within Vero E6 cells and Calu-3 cells, yielding half-maximal effective concentration (EC50) values of 1.99 μM and 1.92 μM, respectively [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-66
T812051807620-38-7
SARS-CoV-2-IN-66 (1), a derivative of vitamin K, functions as an inhibitor of SARS-CoV-2, exhibiting an effective concentration (EC50) of 70.8 μM in VeroE6/TMPRSS2 cells [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-11
T403412722635-28-9
SARS-CoV-2-IN-11 is a highly potent and non-toxic inhibitor of the 3C-like protease (3CLpro) of SARS-CoV-2, demonstrating IC50 and EC50 values of 0.17 nM and 1.45 nM, respectively. This compound targets the essential viral replication enzyme, 3CLpro, making it an attractive candidate for intervention strategies. SARS-CoV-2-IN-11 holds significant promise in the development of specific antivirals against SARS-CoV-2.
  • $970
Backorder
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-65
T81206
SARS-CoV-2-IN-65 (compound 2f (81)) is a potent, orally active reversible inhibitor of SARS-CoV-2 entry, primarily obstructing the RBD:ACE2 interaction and TMPRSS2 activity within the ACE2-dependent pathway in Calu-3 cells [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-68
T812032682897-84-1
SARS-CoV-2-IN-68 (compound 6C) is a covalent inhibitor of both SARS-CoV-2 PLpro and Mpro, exhibiting potent antiviral properties by targeting the Zn-finger domain of PLpro [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-67
T81204
SARS-CoV-2-IN-67 (Compound 16), a derivative of vitamin K, exhibits anti-SARS-CoV-2 properties, with an effective concentration (EC50) of 64.8 μM in VeroE6/TMPRSS2 cells, and inhibits SARS-CoV-2 RdRp activity [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-69
T8120278471-90-6
SARS-CoV-2-IN-69 (Compound 7E) is a potent, non-covalent inhibitor of the SARS-CoV-2 main protease (M^pro) with an EC50 of 7.4 μM and also inhibits the papain-like protease (PL^pro) [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2 Mpro-IN-12
T81210370583-15-6
SARS-CoV-2 Mpro-IN-12 (compound D026) serves as an inhibitor of the main protease (Mpro) of SARS-CoV-2, exhibiting antiviral properties [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2 3CLpro-IN-15
T806573156-41-0
SARS-CoV-2 3CLpro-IN-15 (compound a), a beta-nitrostyrene derivative, acts as an inhibitor of the SARS-CoV-2 3CL protease (3CLpro), effectively inhibiting viral replication and transcription. It is instrumental in the identification of potential anti-COVID-19 lead compounds [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-59
T80636850786-33-3
SARS-CoV-2-IN-59 (compound E07), an imidazoline derivative, is a non-peptide small molecule that inhibits SARS-CoV-2 by targeting its main protease (Mpro). It exhibits robust binding with Mpro residues (Met 165, Gln 166, Met 165, His 41, Gln 189) [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-46
T77510
SARS-CoV-2-IN-46 is a SARS-CoV-2 inhibitor.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2 3CLpro-IN-20
T77652878985-00-3
SARS-CoV-2 3CLpro-IN-20 is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.43 μM,).SARS-CoV-2 3CLpro-IN-20 has potential antiviral activity.
  • $47
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SARS-CoV-2-IN-55
T79570
SARS-CoV-2-IN-55 (compound 65) is an inhibitor of SARS-CoV-2 exhibiting low cytotoxicity, characterized by an IC50 of 0.3 μM, effectuated through direct interaction with VSV-S pseudoparticles [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2 3CLpro-IN-19
T79376
SARS-CoV-2 3CLpro-IN-19 (Compound C5a), a non-covalent, non-peptide inhibitor of the SARS-CoV-2 3CLpro enzyme, exhibits potent in vitro activity with an IC50 of 0.7 μM. It demonstrates broad-spectrum efficacy against infection by Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) in human cells, with EC50 values ranging from 30-69 nM [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-43
T7924331356-11-3
Compound 8h, also known as SARS-CoV-2-IN-43, is a powerful inhibitor effective in obstructing the replication of SARS-CoV-2, exhibiting significant antiviral activity [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-57
T793561265624-68-7
SARS-CoV-2-IN-57 (compound (+)-R-26) is a potent inhibitor of SARS-CoV-2 with an IC50 of 80 nM and demonstrates high affinity for the Sigma Receptor, exhibiting Kis of 13.6 nM (S1R) and 14.4 nM (S2R) [1].
  • $1,520
6-8 weeks
Size
QTY
SARS-CoV-2 3CLpro-IN-14
T79462
SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active inhibitor of SARS-CoV-2 3CLpro, demonstrating potent anti-SARS-CoV-2 properties with an EC50 of 0.18 μM and exhibits minimal cytotoxicity, having a CC50 greater than 50 μM, in Vero E6 cells [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2 3CLpro-IN-17
T79660
Compound 3h, also known as SARS-CoV-2 3CLpro-IN-17, is a selective inhibitor of the SARS-CoV-2 3CL protease, demonstrating an IC50 of 0.322 μM [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2 nsp3-IN-1
T60861
SARS-CoV-2 nsp3-IN-1 (Compound 15c) shows significant selectivity for coronavirus macrodomains, especially SARS-CoV-2 Mac1. SARS-CoV-2 nsp3-IN-1 can inhibit Mac1 ADP-ribosylhydrolase activity that is an inhibitor of Mac1 (IC50 = 6.1 μM) [1].
  • $1,520
10-14 weeks
Size
QTY
SARS-CoV-2 3CLpro-IN-4
T627342505241-31-4
SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a multifunctional inhibitor of SARS CoV-2 3CLpro, exhibiting antiviral, antibacterial, and antifungal activities.
  • $2,140
6-8 weeks
Size
QTY
SARS-CoV-2-IN-10
T403402722634-95-7
SARS-CoV-2-IN-10 is a powerful and non-toxic inhibitor of SARS-CoV-2 3CL protease, with IC50 and EC50 values of 0.13 nM and 1.03 nM, respectively. The SARS-CoV-2 3C-like protease (3CLpro) is a critical enzyme for viral replication and serves as an ideal target for intervention. By targeting the SARS-CoV-2 3CL protease, SARS-CoV-2-IN-10 has the potential to facilitate the development of effective antiviral drugs specific to SARS-CoV-2.
  • $970
Backorder
Size
QTY
SARS-CoV-2 nsp13-IN-2
T62264522660-61-3
SARS-CoV-2 nsp13-IN-2 (Compound C2) is a small molecule inhibitor of SARS-CoV-2 non-structural protein 13 (nsp13) that acts on nsp13 ssDNA+ATPase (IC50: 42 μM).
  • $1,520
6-8 weeks
Size
QTY
SARS-CoV-2 Mpro-IN-5
T72447
SARS-CoV-2 Mpro-IN-5 is a dual inhibitor targeting Main Protease (M Pro) and Cathepsin L (CatL) with IC50 values of 1800 nM and 145 nM, respectively. This compound demonstrates antiviral activity by inhibiting SARS-CoV-2 replication in hACE2 expressing A549 cells, with an IC50 value of 14.7 nM.
  • $1,520
6-8 weeks
Size
QTY
SARS-CoV-2 3CLpro-IN-10
T72312
SARS-CoV-2 3CLpro-IN-10(5d) is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 190 nM, and demonstrates varied efficiency against other coronaviruses with IC50 values of 790 nM for SARS-CoV-1 and 70 nM for MERS-CoV, indicating broad-spectrum antiviral activity.
  • $1,970
8-10 weeks
Size
QTY
SARS-CoV MPro-IN-1
T371742413716-71-7
MProinhibitor 11b is an inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (MPro; IC50= 0.04 μM in a TR-FRET assay).1It reduces viral yield in the culture supernatant of SARS-CoV-2-infected Vero E6 cells (EC50= 0.72 μM). MProinhibitor 11b also reduces viral RNA copy numbers in the same model when used at concentrations ranging from 1.85 to 50 μM. 1.Dai, W., Zhang, B., Jiang, X.-M., et al.Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main proteaseScience368(6497)1331-1335(2020)
  • $198
35 days
Size
QTY
SARS-CoV MPro-IN-2
T7258181418-42-0
SARS-CoV MPro-IN-2 effectively inhibits the SARS-CoV-2 main protease (M pro), crucial for the virus's replication and transcription in host cells, with an IC50 value of 72.07 nM. Given its significant role in processing viral polyproteins, M pro is regarded as a key target in drug discovery efforts. Consequently, SARS-CoV MPro-IN-2 holds promise for COVID-19 research.
  • $1,520
6-8 weeks
Size
QTY
SARS-CoV-2-IN-29 disodium
T74947L
SARS-CoV-2-IN-29 disodium, a diphosphate ester featuring a benzene system and molecular tweezers architecture, demonstrates antiviral efficacy by targeting SARS-CoV-2 with half-maximal inhibitory concentrations (IC50s) of 1.5 μM for virus activity and 1.6 μM for spike pseudoparticle transduction. Additionally, it disrupts liposomal membranes, evidenced by a half-maximal effective concentration (EC50) of 3.0 μM [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-30
T74948
SARS-CoV-2-IN-30, a two-armed diphosphate ester featuring a benzene system and molecular tweezers, demonstrates antiviral properties, achieving IC50 values of 0.6 μM against SARS-CoV-2 activity and 6.9 μM for spike pseudoparticle transduction. Additionally, it disrupts liposomal membranes with an EC50 of 6.9 μM [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-28 disodium
T74946L
SARS-CoV-2-IN-28 disodium, a diphosphate ester featuring a C7 alkyl chain and extended-length molecular tweezers, demonstrates antiviral efficacy by showing IC50 values of 0.4 μM and 1.0 μM against SARS-CoV-2 activity and spike pseudoparticle transduction, respectively. Additionally, it disrupts liposomal membranes with an EC50 of 4.4 μM [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-30 disodium
T74948L
SARS-CoV-2-IN-30 disodium, a benzene-system-based two-armed diphosphate ester featuring molecular tweezers, demonstrates antiviral efficacy, with IC50 values of 0.6 μM against SARS-CoV-2 and 6.9 μM for spike pseudoparticle transduction, respectively. Additionally, it disrupts liposomal membranes, evidenced by an EC50 of 6.9 μM [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-25 disodium
T74943L
SARS-CoV-2-IN-25 (Compound CP026) disodium, a potent inhibitor of SARS-CoV-2 spike pseudoparticle transduction, demonstrates significant efficacy with an IC50 value of 1.6 μM. Additionally, it effectively inhibits enveloped viruses and liposomes, showcasing its broad-spectrum antiviral potential.
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-23 disodium
T74944L
SARS-CoV-2-IN-23 disodium, a medium-length molecular tweezer and two-armed diphosphate ester, demonstrates antiviral properties by inhibiting SARS-CoV-2 activity and spike pseudoparticle transduction with IC50 values of 8.2 μM and 2.6 μM, respectively. Additionally, it disrupts liposomal membranes with an EC50 of 4.4 μM [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-22
T628342710278-53-6
SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus inhibitor (IC50: 16.96 μM).
  • $1,520
10-14 weeks
Size
QTY
Anti-SARS-CoV-2 Spike mAb (CR3022)
T36654
Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody derived from CHO cells. It specifically targets the S1 domain of the Spike protein in both SARS-CoV and SARS-CoV-2.
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-39
T775162882823-03-0
SARS-CoV-2-IN-39 is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 has antiviral activity and inhibits SARS-CoV-2 by inhibiting SKP2 protein and stabilizing BECN1.
  • $48
In Stock
Size
QTY
SARS-CoV-2-IN-17
T616132761911-44-6
SARS-CoV-2-IN-17 (Compound 16) is a highly effective inhibitor of SARS-CoV-2 nucleocapsid protein (NPro). It demonstrates potent anti-viral activity, with an EC50 value of 2.18 μM. Furthermore, SARS-CoV-2-IN-17 binds to NPro with a low Kd value of 7.82 μM, highlighting its potency as a NPro ligand [1].
  • $1,520
6-8 weeks
Size
QTY
SARS-CoV-2 nsp13-IN-4
T62031923140-39-0
SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective small-molecule inhibitor of nsp13 helicase. SARS-CoV-2 nsp13-IN-4 inhibits the ssDNA+ ATPase activity of nsp13 with an IC 50 of 57 μM. SARS-CoV-2 nsp13-IN-4 can provide a broad-spectrum antiviral effect.
  • $1,520
6-8 weeks
Size
QTY
SARS-CoV-2-IN-6
T60785
SARS-CoV-2-IN-6 is an inhibitor of SARS-CoV-2 3CLpro with the IC 50 value of 73 nM.
  • $998
10-14 weeks
Size
QTY
SARS-CoV-2-IN-14
T6053822203-98-1
SARS-CoV-2-IN-14 is a potent and oral inhibitor of SARS-CoV-2 (IC50:0.39 μM), which is an analogue of niclosamide. SARS-CoV-2-IN-14 was more stable than niclosamide in the determination of human plasma and liver S9 enzyme. Oral administration of SARS-CoV-2-IN-14 can improve its bioavailability and half-life.
  • $39
In Stock
Size
QTY
SARS-CoV-2-IN-18
T60962184904-82-3
SARS-CoV-2-IN-18 (Compound 26) is a potent inhibitor of SARS-CoV-2 3C-like protease (IC50 = 45 nM) [1].
  • $1,520
6-8 weeks
Size
QTY
SARS-CoV-2 3CLpro-IN-2
T633852765088-93-3
SARS-CoV-2 3CLpro-IN-2 is a potent inhibitor of the 3CL protease pair and has shown research potential for SARS-CoV-2 disease.
  • $1,400
8-10 weeks
Size
QTY
SARS-CoV-IN-1
T12837888958-25-6
SARS-CoV-IN-1 is an effective SARS-CoV replication inhibitor(EC50 of 4.9 μM in Vero cells).
  • $1,780
6-8 weeks
Size
QTY
SARS-CoV-2-IN-50
T79228
SARS-CoV-2-IN-50 (Compound X77C) is a potent inhibitor of the SARS-CoV-2 main protease (M^pro), exhibiting high affinity for the enzyme's catalytic site [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-56
T79329
SARS-CoV-2-IN-56 (Compound 63) is a SARS-CoV-2 inhibitor with antiviral activity, demonstrating inhibition of the virus in Vero E6 cells with an IC50 of 0.7 μM [1].
  • Inquiry Price
Size
QTY
SARS-CoV-2-IN-41
T792182920904-06-7
SARS-CoV-2-IN-41 (compound 2) is a potent inhibitor of SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.022 µM and demonstrating antiviral efficacy [1].
  • $1,520
6-8 weeks
Size
QTY
SARS-CoV-2-IN-49
T79227
SARS-CoV-2-IN-49 acts as an irreversible covalent inhibitor targeting the main protease of SARS-CoV-2 [1].
  • Inquiry Price
Size
QTY